{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,22]],"date-time":"2025-02-22T00:43:22Z","timestamp":1740185002439,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T00:00:00Z","timestamp":1673222400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006447","name":"University of Zurich","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006447","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Der zweite Teil des Artikels widmet sich den molekularen Charakteristiken des epithelial-myoepithelialen Karzinoms, des polymorphen Adenokarzinoms, des myoepithelialen Karzinoms, des Basalzelladenokarzinoms sowie des Speichelgangkarzinoms. Zus\u00e4tzlich werden die neu aufgekommenen Entit\u00e4ten des muzin\u00f6sen Adenokarzinoms, des sklerosierenden mikrozystischen Adenokarzinoms und des mikrosekretorischen Adenokarzinoms zusammengefasst. Auch bei den meisten dieser Entit\u00e4ten kann der molekulare Genotyp diagnostisch sehr hilfreich sein. Eine \u00dcberexpression des Androgenrezeptors und\/oder von \u201ehuman epidermal growth factor receptor 2\u201c (HER2)\/neu kann dabei im geeigneten histopathologischen Kontext nicht nur zur Diagnoseuntermauerung eines Speichelgangkarzinoms dienen, sondern potenziell auch gezielt therapeutisch angegangen werden.<\/jats:p>","DOI":"10.1007\/s00292-022-01171-4","type":"journal-article","created":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T16:11:23Z","timestamp":1673280683000},"page":"70-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Speicheldr\u00fcsenkarzinome\u00a0\u2013 ein aktueller \u00dcberblick","Salivary gland tumors\u2014an\u00a0overview"],"prefix":"10.1007","volume":"44","author":[{"given":"Niels J.","family":"Rupp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra N.","family":"Freiberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,9]]},"reference":[{"issue":"7","key":"1171_CR1","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1097\/PAS.0000000000001258","volume":"43","author":"M Urano","year":"2019","unstructured":"Urano\u00a0M, Nakaguro\u00a0M, Yamamoto\u00a0Y, Hirai\u00a0H, Tanigawa\u00a0M, Saigusa\u00a0N et al (2019) Diagnostic significance of HRAS mutations in epithelial-myoepithelial carcinomas exhibiting a\u00a0broad histopathologic spectrum. Am J Surg Pathol 43(7):984\u2013994","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"1171_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12105-019-01055-9","volume":"14","author":"NJ Rupp","year":"2020","unstructured":"Rupp\u00a0NJ, Brada\u00a0M, Sk\u00e1lov\u00e1\u00a0A, Bode\u00a0B, Broglie\u00a0MA, Morand\u00a0GB et al (2020) New insights into tumor heterogeneity: a case of solid-oncocytic epithelial-myoepithelial carcinoma of the parotid gland harboring a HRAS and heterogeneous terminating ARID1A mutation. Head Neck Pathol 14(2):554\u2013558. https:\/\/doi.org\/10.1007\/s12105-019-01055-9","journal-title":"Head Neck Pathol"},{"issue":"1","key":"1171_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.path.2020.09.006","volume":"14","author":"MS Hsieh","year":"2021","unstructured":"Hsieh\u00a0MS, Bishop\u00a0JA, Yu Fong Chang\u00a0J (2021) Sialadenoma papilliferum. Surg Pathol Clin 14(1):43\u201351","journal-title":"Surg Pathol Clin"},{"issue":"7","key":"1171_CR4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/PAS.0000000000001673","volume":"45","author":"M Nakaguro","year":"2021","unstructured":"Nakaguro\u00a0M, Tanigawa\u00a0M, Hirai\u00a0H, Yamamoto\u00a0Y, Urano\u00a0M, Takahashi\u00a0RH et al (2021) The diagnostic utility of RAS Q61R mutation-specific immunohistochemistry in epithelial-myoepithelial carcinoma. Am J Surg Pathol 45(7):885\u2013894","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1171_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/PAS.0000000000000933","volume":"42","author":"S El Hallani","year":"2018","unstructured":"El Hallani\u00a0S, Udager\u00a0AM, Bell\u00a0D, Fonseca\u00a0I, Thompson\u00a0LDR, Assaad\u00a0A et al (2018) Epithelial-myoepithelial carcinoma: frequent morphologic and molecular evidence of preexisting pleomorphic adenoma, common HRAS mutations in PLAG1-intact and HMGA2-intact cases, and occasional TP53, FBXW7, and SMARCB1 alterations in high-grade cases. Am J Surg Pathol 42(1):18\u201327","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1171_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41379-019-0351-4","volume":"33","author":"APM Sebastiao","year":"2020","unstructured":"Sebastiao\u00a0APM, Xu\u00a0B, Lozada\u00a0JR, Pareja\u00a0F, Geyer\u00a0FC, Da Cruz Paula\u00a0A et\u00a0al (2020) Histologic spectrum of polymorphous adenocarcinoma of the salivary gland harbor genetic alterations affecting PRKD genes. Mod Pathol 33(1):65\u201373","journal-title":"Mod Pathol"},{"issue":"5","key":"1171_CR7","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.neo.2021.03.008","volume":"23","author":"SN Freiberger","year":"2021","unstructured":"Freiberger\u00a0SN, Brada\u00a0M, Fritz\u00a0C, H\u00f6ller\u00a0S, Vogetseder\u00a0A, Horcic\u00a0M et\u00a0al (2021) SalvGlandDx\u2014a\u00a0comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia 23(5):473\u2013487","journal-title":"Neoplasia"},{"issue":"1","key":"1171_CR8","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41467-017-01178-z","volume":"8","author":"MG Dalin","year":"2017","unstructured":"Dalin\u00a0MG, Katabi\u00a0N, Persson\u00a0M, Lee\u00a0KW, Makarov\u00a0V, Desrichard\u00a0A et al (2017) Multi-dimensional genomic analysis of myoepithelial carcinoma identifies prevalent oncogenic gene fusions. Nat Commun 8(1):1197","journal-title":"Nat Commun"},{"issue":"2","key":"1171_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/gcc.23009","volume":"61","author":"NJ Rupp","year":"2022","unstructured":"Rupp\u00a0NJ, H\u00f6ller\u00a0S, Brada\u00a0M, Vital\u00a0D, Morand\u00a0GB, Broglie\u00a0MA et al (2022) Expanding the clinicopathological spectrum of TGFBR3-PLAG1 rearranged salivary gland neoplasms with myoepithelial differentiation including evidence of high-grade transformation. Genes Chromosomes Cancer 61(2):94\u2013104","journal-title":"Genes Chromosomes Cancer"},{"issue":"10","key":"1171_CR10","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/s41379-020-0576-2","volume":"33","author":"SA Mueller","year":"2020","unstructured":"Mueller\u00a0SA, Gauthier\u00a0MEA, Blackburn\u00a0J, Grady\u00a0JP, Kraitsek\u00a0S, Hajdu\u00a0E et\u00a0al (2020) Molecular patterns in salivary duct carcinoma identify prognostic subgroups. Mod Pathol 33(10):1896\u20131909","journal-title":"Mod Pathol"},{"issue":"10","key":"1171_CR11","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1097\/PAS.0000000000001688","volume":"45","author":"LM Rooper","year":"2021","unstructured":"Rooper\u00a0LM, Argyris\u00a0PP, Thompson\u00a0LDR, Gagan\u00a0J, Westra\u00a0WH, Jordan\u00a0RC et\u00a0al (2021) Salivary mucinous adenocarcinoma is a histologically diverse single entity with recurrent AKT1 E17K mutations: clinicopathologic and molecular characterization with proposal for a unified classification. Am J Surg Pathol 45(10):1337\u20131347","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"1171_CR12","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s12105-021-01331-7","volume":"15","author":"JA Bishop","year":"2021","unstructured":"Bishop\u00a0JA, Sajed\u00a0DP, Weinreb\u00a0I, Dickson\u00a0BC, Bilodeau\u00a0EA, Agaimy\u00a0A et\u00a0al (2021) Microsecretory adenocarcinoma of salivary glands: an expanded series of 24 cases. Head Neck Pathol 15(4):1192\u20131201. https:\/\/doi.org\/10.1007\/s12105-021-01331-7","journal-title":"Head Neck Pathol"},{"key":"1171_CR13","unstructured":"WHO (2022) WHO classification of tumours editorial board. Head and neck tumours. https:\/\/tumourclassification.iarc.who.int\/chapters\/52. Zugegriffen: 1. Mai 2022"},{"issue":"1","key":"1171_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.path.2020.09.011","volume":"14","author":"N Katabi","year":"2021","unstructured":"Katabi\u00a0N, Xu\u00a0B (2021) Polymorphous adenocarcinoma. Surg Pathol Clin 14(1):127\u2013136","journal-title":"Surg Pathol Clin"},{"issue":"4","key":"1171_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/PAS.0000000000001431","volume":"44","author":"B Xu","year":"2020","unstructured":"Xu\u00a0B, Barbieri\u00a0AL, Bishop\u00a0JA, Chiosea\u00a0SI, Dogan\u00a0S, Di Palma\u00a0S et\u00a0al (2020) Histologic classification and molecular signature of polymorphous adenocarcinoma (PAC) and cribriform adenocarcinoma of salivary gland (CASG): an international interobserver study. Am J Surg Pathol 44(4):545\u2013552","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1171_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.path.2020.09.008","volume":"14","author":"B Xu","year":"2021","unstructured":"Xu\u00a0B, Katabi\u00a0N (2021) Myoepithelial carcinoma. Surg Pathol Clin 14(1):67\u201373","journal-title":"Surg Pathol Clin"},{"issue":"5","key":"1171_CR17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/PAS.0000000000001218","volume":"43","author":"B Xu","year":"2019","unstructured":"Xu\u00a0B, Mneimneh\u00a0W, Torrence\u00a0DE, Higgins\u00a0K, Klimstra\u00a0D, Ghossein\u00a0R et\u00a0al (2019) Misinterpreted myoepithelial carcinoma of salivary gland: a challenging and potentially significant pitfall. Am J Surg Pathol 43(5):601\u2013609","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1171_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/PAS.0000000000001591","volume":"45","author":"A Sk\u00e1lov\u00e1","year":"2021","unstructured":"Sk\u00e1lov\u00e1\u00a0A, Agaimy\u00a0A, Vanecek\u00a0T, Baneckov\u00e1\u00a0M, Laco\u00a0J, Pt\u00e1kov\u00e1\u00a0N et\u00a0al (2021) Molecular profiling of clear cell myoepithelial carcinoma of salivary glands with EWSR1 rearrangement identifies frequent PLAG1 gene fusions but no EWSR1 fusion transcripts. Am J Surg Pathol 45(1):1\u201313","journal-title":"Am J Surg Pathol"},{"key":"1171_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.humpath.2020.07.009","volume":"103","author":"M Ban\u011b\u010dkov\u00e1","year":"2020","unstructured":"Ban\u011b\u010dkov\u00e1\u00a0M, Uro-Coste\u00a0E, Pt\u00e1kov\u00e1\u00a0N, \u0160teiner\u00a0P, Stanowska\u00a0O, Benincasa\u00a0G et al (2020) What is hiding behind S100 protein and SOX10 positive oncocytomas? Oncocytic pleomorphic adenoma and myoepithelioma with novel gene fusions in a\u00a0subset of cases. Hum Pathol 103:52\u201362","journal-title":"Hum Pathol"},{"issue":"1","key":"1171_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.path.2020.09.005","volume":"14","author":"RA Robinson","year":"2021","unstructured":"Robinson\u00a0RA (2021) Basal cell adenoma and basal cell adenocarcinoma. Surg Pathol Clin 14(1):25\u201342","journal-title":"Surg Pathol Clin"},{"issue":"8","key":"1171_CR21","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1097\/PAS.0000000000000669","volume":"40","author":"VY Jo","year":"2016","unstructured":"Jo\u00a0VY, Sholl\u00a0LM, Krane\u00a0JF (2016) Distinctive patterns of CTNNB1 (\u03b2-Catenin) alterations in salivary gland basal cell adenoma and basal cell adenocarcinoma. Am J Surg Pathol 40(8):1143\u20131150","journal-title":"Am J Surg Pathol"},{"key":"1171_CR22","doi-asserted-by":"publisher","first-page":"580141","DOI":"10.3389\/fonc.2020.580141","volume":"10","author":"L Di Villeneuve","year":"2020","unstructured":"Di Villeneuve\u00a0L, Souza\u00a0IL, Tolentino\u00a0FDS, Ferrarotto\u00a0R, Schvartsman\u00a0G (2020) Salivary gland carcinoma: novel targets to overcome treatment resistance in advanced disease. Front Oncol 10:580141","journal-title":"Front Oncol"},{"issue":"6","key":"1171_CR23","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/PAS.0000000000001636","volume":"45","author":"LM Rooper","year":"2021","unstructured":"Rooper\u00a0LM, Mansour\u00a0M, Yonescu\u00a0R, Oliai\u00a0BR, Bishop\u00a0JA, Westra\u00a0WH (2021) The decline of salivary adenocarcinoma not otherwise specified as a\u00a0tumor entity: reclassification using contemporary immunohistochemical profiling and diagnostic criteria. Am J Surg Pathol 45(6):753\u2013764","journal-title":"Am J Surg Pathol"},{"issue":"8","key":"1171_CR24","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1097\/PAS.0000000000001080","volume":"42","author":"A Agaimy","year":"2018","unstructured":"Agaimy\u00a0A, Mueller\u00a0SK, Bumm\u00a0K, Iro\u00a0H, Moskalev\u00a0EA, Hartmann\u00a0A et\u00a0al (2018) Intraductal papillary mucinous neoplasms of minor salivary glands with AKT1 p.Glu17Lys mutation. Am J Surg Pathol 42(8):1076\u20131082","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1171_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12105-022-01420-1","volume":"16","author":"A Sk\u00e1lov\u00e1","year":"2022","unstructured":"Sk\u00e1lov\u00e1\u00a0A, Hyrcza\u00a0MD, Leivo\u00a0I (2022) Update from the 5th edition of the world health organization classification of head and neck tumors: salivary glands. Head Neck Pathol 16(1):40\u201353","journal-title":"Head Neck Pathol"},{"issue":"4","key":"1171_CR26","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s12105-016-0731-8","volume":"10","author":"AM Mills","year":"2016","unstructured":"Mills\u00a0AM, Policarpio-Nicholas\u00a0MLC, Agaimy\u00a0A, Wick\u00a0MR, Mills\u00a0SE (2016) Sclerosing microcystic adenocarcinoma of the head and neck mucosa: a neoplasm closely resembling microcystic adnexal carcinoma. Head Neck Pathol 10(4):501\u2013508","journal-title":"Head Neck Pathol"},{"issue":"11","key":"1171_CR27","doi-asserted-by":"publisher","first-page":"6375","DOI":"10.21873\/anticanres.14658","volume":"40","author":"R Jiang","year":"2020","unstructured":"Jiang\u00a0R, Marquez\u00a0J, Tower\u00a0JI, Jacobs\u00a0D, Chen\u00a0W, Mehra\u00a0S et\u00a0al (2020) Sequencing of sclerosing microcystic adenocarcinoma identifies mutational burden and somatic variants associated with tumorigenesis. Anticancer Res 40(11):6375\u20136379","journal-title":"Anticancer Res"},{"issue":"8","key":"1171_CR28","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1097\/PAS.0000000000001273","volume":"43","author":"JA Bishop","year":"2019","unstructured":"Bishop\u00a0JA, Weinreb\u00a0I, Swanson\u00a0D, Westra\u00a0WH, Qureshi\u00a0HS, Sciubba\u00a0J et al (2019) Microsecretory adenocarcinoma: a novel salivary gland tumor characterized by a\u00a0recurrent: MEF2C-SS18: fusion. Am J Surg Pathol 43(8):1023\u20131032","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"1171_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s12105-020-01280-7","volume":"15","author":"JA Bishop","year":"2021","unstructured":"Bishop\u00a0JA, Koduru\u00a0P, Veremis\u00a0BM, Oliai\u00a0BR, Weinreb\u00a0I, Rooper\u00a0LM et al (2021) SS18 break-apart fluorescence in situ hybridization is a practical and effective method for diagnosing microsecretory adenocarcinoma of salivary glands. Head Neck Pathol 15(3):723\u2013726. https:\/\/doi.org\/10.1007\/s12105-020-01280-7","journal-title":"Head Neck Pathol"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-022-01171-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-022-01171-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-022-01171-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T08:36:56Z","timestamp":1701679016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-022-01171-4"}},"subtitle":["Fortschritte in der molekularen Typisierung Teil\u00a0II","Advances in molecular characterization: Part II"],"short-title":[],"issued":{"date-parts":[[2023,1,9]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1007\/s00292-022-01171-4","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"type":"print","value":"2731-7188"},{"type":"electronic","value":"2731-7196"}],"subject":[],"published":{"date-parts":[[2023,1,9]]},"assertion":[{"value":"2 August 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>N.\u00a0Rupp<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Das SalvGlandDx NGS Panel wurde mithilfe eines Grants der Iten-Kohaut-Stiftung entwickelt. \u2013\u00a0Eingeladener Referent Schnittseminare und Jahrestagungen der IAP Schweiz\/Schweizerischen Gesellschaft f\u00fcr Pathologie (Reise\u2011\/\u00dcbernachtungskosten und bezahlte Teilnehmergeb\u00fchren); Eingeladener Referent Europ\u00e4ischer Kongress f\u00fcr Pathologie (ECP; bezahlte\/reduzierte Teilnehmergeb\u00fchren); Teilnahme als eingeladener Referent beim DGHNO-Jahreskongress 2022 in Hannover (Reise\u2011\/\u00dcbernachtungskosten und bezahlte Teilnehmergeb\u00fchren).\u00a0\u2013 Teilnahme am Advisory Board der F.\u00a0Hoffmann-La Roche AG (Honorar). \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Oberarzt mit erweiterter Verantwortung, Institut f\u00fcr Pathologie und Molekularpathologie, Universit\u00e4tsspital Z\u00fcrich, Z\u00fcrich, Schweiz; Assistenzprofessor f\u00fcr Theragnostische Tumorpathologie, Universit\u00e4t Z\u00fcrich, Z\u00fcrich, Schweiz; Lehrauftrag \u201eTumorpathologie\u201c an der Eidgen\u00f6ssischen Technischen Hochschule (ETH) Z\u00fcrich, Schweiz | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Pathologie (DGP); Sprecher der Arbeitsgruppe Kopf-Hals-Pathologie der DGP; Schweizerische Gesellschaft f\u00fcr Pathologie; Koautor IARC-WHO-Klassifikation \u201eHead & Neck Tumours, 5th Edition\u201c. <b>S.N.\u00a0Freiberger-Rupp<\/b>: A.\u00a0Finanzielle Interessen: S.\u00a0N.\u00a0Freiberger-Rupp gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: wissenschaftliche Mitarbeiterin, Institut f\u00fcr Pathologie und Molekularpathologie, Universit\u00e4tsspital Z\u00fcrich, Z\u00fcrich, Schweiz | Mitgliedschaft: Deutsche Gesellschaft f\u00fcr Pathologie (DGP).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}